In this early phase clinical trial (NCT00933777), the combination of sorafenib (a multi-TKI) with everolimus (mTOR inhibitor) did not achieve any partial response in NSCLC patients harboring KRAS mutation, assessed by CT-scans (62). This evidence concerns the gene KRAS and non-small cell lung carcinoma.